You need JavaScript to view this

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study

Abstract

Mucinous ovarian carcinoma have a poorer prognosis compared with other histological subtypes. The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer. The SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian cancer observed in the years 2000–2002 in 37 Italian centres. Data were collected between April and September 2005. Patients with recurrent ovarian cancer with > 6 months of platinum free interval were considered eligible. Twenty patients with mucinous histotype and 388 patients with other histotypes were analyzed. At baseline, mucinous tumours differed from the others for an higher number of patients with lower tumor grading (p = 0.0056) and less advanced FIGO stage (p = 0.025). At time of recurrence, a statistically significant difference was found in performance status (worse in mucinous, p = 0.024). About 20% of patients underwent secondary cytoreduction in both groups, but a lower number of patients were optimally debulked in the mucinous group (p = 0.03). Patients with mucinous cancer received more frequently single agent platinum than platinum based-combination therapy or other non-platinum schedules as second line therapy (p = 0.026), with a  More>>
Authors:
Pignata, Sandro; [1]  Ghezzi, Fabio; [2]  Manzione, Luigi; [3]  Lauria, Rossella; [4]  Breda, Enrico; [5]  Alletti, Desiderio Gueli; [6]  Ballardini, Michela; [7]  Lombardi, Alessandra Vernaglia; [8]  Sorio, Roberto; [9]  Mangili, Giorgia; [10]  Priolo, Domenico; [11]  Ferrandina, Gabriella; [12]  Magni, Giovanna; [13]  Morabito, Alessandro; [1]  Scarfone, Giovanna; [14]  Scollo, Paolo; [15]  Odicino, Franco; [16]  Cormio, Gennaro; [17]  Katsaros, Dionyssios; [18]  Villa, Antonella; [19]  Mereu, Liliana [20] 
  1. Istituto Nazionale Tumori, Napoli (Italy)
  2. Università dell'Insubria Clinica Ginecologia e Ostetrica, Varese (Italy)
  3. Azienda Ospedaliera S. Carlo, Oncologia Medica, Potenza (Italy)
  4. Università Federico II, Oncologia Medica, Napoli (Italy)
  5. Ospedale S. Giovanni-Fatebene Fratelli-Isola Tiberina, Oncologia Medica, Roma (Italy)
  6. A.O. Vincenzo Cervello, Ostetricia e Ginecologia, Palermo (Italy)
  7. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST, Meldola (FC) (Italy)
  8. Casa di cura Malzoni, Ginecologia Oncologica, Avellino (Italy)
  9. CRO AVIANO, Oncologia Medica, Aviano (Italy)
  10. Ospedale S. Raffaele, Ginecologia Oncologica Medica, Milano (Italy)
  11. Ospedale S. Vincenzo, Oncologia Medica, Taormina (Italy)
  12. Policlinico Agostino Gemelli, Ginecologia Oncologica, Roma (Italy)
  13. QBGROUP spa, Padova (Italy)
  14. Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Clinica Ostetrico-Ginecologica, Milano (Italy)
  15. A.O. S. Cannizzaro, Ginecologia ed Ostetricia, Catania (Italy)
  16. A.O. Spedali Civili-Università degli Studi di Brescia, II Ginecologia ed Ostetricia, Brescia (Italy)
  17. Azienda Ospedaliera Policlinico, II Ginecologia e Ostetricia, Bari (Italy)
  18. Azienda Ospedaliera O.I.R.M.-S. Anna, Ginecologica Oncologica, Università di Torino (Italy)
  19. Ospedali Riuniti di Bergamo, U.O. di Ginecologia, Bergamo (Italy)
  20. Ospedale Policlinico S. Matteo, Ostetrica e Ginecologica, Pavia (Italy)
Publication Date:
Sep 01, 2008
Product Type:
Journal Article
Resource Relation:
Journal Name: BMC Cancer (Online); Journal Volume: 8; Other Information: PMCID: PMC2538544; PUBLISHER-ID: 1471-2407-8-252; PMID: 18761742; OAI: oai:pubmedcentral.nih.gov:2538544; Copyright (c) 2008 Pignata et al; licensee BioMed Central Ltd.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.; Country of input: International Atomic Energy Agency (IAEA)
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; CARCINOMAS; CHEMOTHERAPY; PATIENTS; PERFORMANCE; PLATINUM; SCHEDULES
OSTI ID:
22386447
Country of Origin:
United Kingdom
Language:
English
Other Identifying Numbers:
Journal ID: ISSN 1471-2407; TRN: GB15$2762092026
Availability:
Available from http://dx.doi.org/10.1186/1471-2407-8-252; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538544
Submitting Site:
INIS
Size:
page(s) 252
Announcement Date:
Oct 16, 2015

Citation Formats

Pignata, Sandro, Ghezzi, Fabio, Manzione, Luigi, Lauria, Rossella, Breda, Enrico, Alletti, Desiderio Gueli, Ballardini, Michela, Lombardi, Alessandra Vernaglia, Sorio, Roberto, Mangili, Giorgia, Priolo, Domenico, Ferrandina, Gabriella, Magni, Giovanna, Morabito, Alessandro, Scarfone, Giovanna, Scollo, Paolo, Odicino, Franco, Cormio, Gennaro, Katsaros, Dionyssios, Villa, Antonella, and Mereu, Liliana. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. United Kingdom: N. p., 2008. Web. doi:10.1186/1471-2407-8-252.
Pignata, Sandro, Ghezzi, Fabio, Manzione, Luigi, Lauria, Rossella, Breda, Enrico, Alletti, Desiderio Gueli, Ballardini, Michela, Lombardi, Alessandra Vernaglia, Sorio, Roberto, Mangili, Giorgia, Priolo, Domenico, Ferrandina, Gabriella, Magni, Giovanna, Morabito, Alessandro, Scarfone, Giovanna, Scollo, Paolo, Odicino, Franco, Cormio, Gennaro, Katsaros, Dionyssios, Villa, Antonella, & Mereu, Liliana. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. United Kingdom. doi:10.1186/1471-2407-8-252.
Pignata, Sandro, Ghezzi, Fabio, Manzione, Luigi, Lauria, Rossella, Breda, Enrico, Alletti, Desiderio Gueli, Ballardini, Michela, Lombardi, Alessandra Vernaglia, Sorio, Roberto, Mangili, Giorgia, Priolo, Domenico, Ferrandina, Gabriella, Magni, Giovanna, Morabito, Alessandro, Scarfone, Giovanna, Scollo, Paolo, Odicino, Franco, Cormio, Gennaro, Katsaros, Dionyssios, Villa, Antonella, and Mereu, Liliana. 2008. "Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study." United Kingdom. doi:10.1186/1471-2407-8-252. https://www.osti.gov/servlets/purl/10.1186/1471-2407-8-252.
@misc{etde_22386447,
title = {Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study}
author = {Pignata, Sandro, Ghezzi, Fabio, Manzione, Luigi, Lauria, Rossella, Breda, Enrico, Alletti, Desiderio Gueli, Ballardini, Michela, Lombardi, Alessandra Vernaglia, Sorio, Roberto, Mangili, Giorgia, Priolo, Domenico, Ferrandina, Gabriella, Magni, Giovanna, Morabito, Alessandro, Scarfone, Giovanna, Scollo, Paolo, Odicino, Franco, Cormio, Gennaro, Katsaros, Dionyssios, Villa, Antonella, and Mereu, Liliana}
abstractNote = {Mucinous ovarian carcinoma have a poorer prognosis compared with other histological subtypes. The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer. The SOCRATES study retrospectively assessed the pattern of care of a cohort of patients with recurrent platinum-sensitive ovarian cancer observed in the years 2000–2002 in 37 Italian centres. Data were collected between April and September 2005. Patients with recurrent ovarian cancer with > 6 months of platinum free interval were considered eligible. Twenty patients with mucinous histotype and 388 patients with other histotypes were analyzed. At baseline, mucinous tumours differed from the others for an higher number of patients with lower tumor grading (p = 0.0056) and less advanced FIGO stage (p = 0.025). At time of recurrence, a statistically significant difference was found in performance status (worse in mucinous, p = 0.024). About 20% of patients underwent secondary cytoreduction in both groups, but a lower number of patients were optimally debulked in the mucinous group (p = 0.03). Patients with mucinous cancer received more frequently single agent platinum than platinum based-combination therapy or other non-platinum schedules as second line therapy (p = 0.026), with a response rate lower than in non-mucinous group (36.4% vs 62.6%, respectively, p = 0.04). Median time to progression and overall survival were worse for mucinous ovarian cancer. Finally, mucinous cancer received a lower number of chemotherapy lines (p = 0.0023). This analysis shows that platinum sensitive mucinous ovarian cancer has a poor response to chemotherapy. Studies dedicated to this histological subgroup are needed.}
doi = {10.1186/1471-2407-8-252}
journal = {BMC Cancer (Online)}
volume = {8}
journal type = {AC}
place = {United Kingdom}
year = {2008}
month = {Sep}
}